Tech Company Financing Transactions
Zikani Therapeutics Funding Round
Zikani Therapeutics closed a $7.5 million Series A funding round on 4/21/2020. Investors included Advent Life Sciences, Gurnet Point Capital and Roche Venture Fund.
Transaction Overview
Company Name
Announced On
4/21/2020
Transaction Type
Venture Equity
Amount
$7,500,000
Round
Series A
Investors
Proceeds Purpose
Zikani will use the proceeds to advance its current nonsense mutation readthrough programs from lead optimization to candidate selection.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
480 Arsenal Way 130
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
Zikani Therapeutics is an emerging leader in the science of ribosome modulation, leveraging its innovative TURBO-ZMTM chemistry technology platform to develop novel Ribosome Modulating Agents (RMAs) as therapeutics for people with limited treatment options.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sumit Aggarwal
Chief Financial Officer
Daniel Geffken
Vice President
Roger Clark
VP - Bus. Development
Karen LaRochelle
VP - Bus. Development
Joseph Newman
Browse more venture capital transactions:
Prev: 4/21/2020: Ureeka venture capital transaction
Next: 4/21/2020: NoBroker venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs